BETA: Please send your feedback!
REGENXBIO
RGNX:NAS
Biotechnology
$0
SMALL cap
$27.75
(-1.68%)
-0.39%
since start of 2020
-10.75
About
Biotechnology
Founded 2008
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
website
Headquarters
Executives
| Name | Title | Gender |
| Patrick J. Christmas | Senior Vice President & General Counsel | Male |
| Donald J. Hayden, Jr., MBA | Chairman | Male |
| Kenneth T. Mills | President, Chief Executive Officer & Director | Male |
| Vit Vasista, MBA | CFO & Principal Accounting Officer | Male |
| Olivier Danos, PhD | Chief Scientific Officer | Male |
| Stephen Yoo, MD | Chief Medical Officer | Male |
| Kimberly Sloan | Senior Vice President-Human Resources | Female |
| Lynne Fahey McGrath, PhD | Vice President-Regulatory Affairs | Female |
| James M. Wilson, MD, PhD | Founder | null |
| Rickey Reinhardt, MD, PhD | Vice President-Clinical Research & Development | null |
| Jerome W. Jackson, MBA | Vice President-Information Technology | Male |
Mindful Investing Summary
REGENXBIO - Competitors and Related Companies
How REGENXBIO stacks up to its peers in the Biotechnology industry or with competing business segments.
REGENXBIO
RGNX:NAS
Biotechnology
$0
SMALL cap
$27.75
(-1.68%)
-0.39%
since start of 2020
-10.75
Invivo Therapeutics Holdings
NVIV:NAS
Biotechnology
$929440.00
MICRO cap
$1.57
(0.03%)
-0.75%
since start of 2020
-475.76
Medivir
MVIR.B-SE:OME
Pharmaceuticals: Other
—
MICRO cap
(—)
—
since start of 2020
—
Oncolytics Biotech
ONC-CA:TSE
Biotechnology
—
MICRO cap
(—)
—
since start of 2020
—
OpGen
OPGN:NAS
Biotechnology
$29.59mm
MICRO cap
$2.48
(-0.09%)
1.12%
since start of 2020
-0.16